22,200 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 22,200 shares of the biopharmaceutical company's stock, valued at approximately $729,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Two Sigma Investments LP purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth $3,594,000. Tema Etfs LLC purchased a new position in Agios Pharmaceuticals during the 4th quarter valued at about $846,000. Silvercrest Asset Management Group LLC grew its position in Agios Pharmaceuticals by 4.1% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 83,157 shares of the biopharmaceutical company's stock valued at $2,733,000 after acquiring an additional 3,272 shares in the last quarter. ProShare Advisors LLC increased its stake in Agios Pharmaceuticals by 32.6% during the fourth quarter. ProShare Advisors LLC now owns 18,619 shares of the biopharmaceutical company's stock worth $612,000 after purchasing an additional 4,577 shares during the period. Finally, Paradigm Biocapital Advisors LP acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $9,084,000.

Agios Pharmaceuticals Stock Down 0.4%

Agios Pharmaceuticals stock traded down $0.13 during midday trading on Thursday, reaching $33.91. The company's stock had a trading volume of 158,730 shares, compared to its average volume of 671,296. The company has a market cap of $1.96 billion, a P/E ratio of 2.99 and a beta of 0.77. The business has a 50-day simple moving average of $28.75 and a 200-day simple moving average of $34.79. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. Scotiabank reduced their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $56.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.